drugset / Trial / NCT00356356

16.0040 Ankylosing Spondylitis Study

NCT00356356

Phase 3 Completed 257 enrolled Amgen Immunex Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate extended safety and efficacy of etanercept in adults with Ankylosing Spondylitis.

Timeline

Start
2002-04
Primary completion
2006-08
Completion
2006-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous